Alvogen, Inc. recalled Levothyroxine Sodium Tablets on January 21, 2026, after a pharmacy reported a mix-up with dosages. Some bottles contained 88 mcg tablets instead of the prescribed 150 mcg. The recall affects 1,000 tablets from lot # MHA21825, with an expiration date of December 31, 2027.
Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.
Consumers and healthcare providers should stop using this product immediately. Contact Alvogen, Inc or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall includes Levothyroxine Sodium Tablets, USP, 150 mcg, in bottles of 1,000 tablets. These were manufactured by LLOYD, Inc. in Shenandoah, IA, and distributed by Alvogen, Inc. in Pine Brook, NJ.
The product mix-up presents a high risk for patients requiring a specific dosage of Levothyroxine Sodium. Taking the incorrect dosage can lead to serious health complications for individuals with thyroid conditions.
Only one incident of product mix-up has been reported, affecting a single bottle. There are no additional reported injuries or health complications at this time.
Consumers and healthcare providers should stop using the recalled tablets immediately. Contact Alvogen, Inc. or your healthcare provider for further guidance.
For more information, consumers can visit the FDA recall page at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0259-2026 or contact Alvogen, Inc.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.